OraSure Technologies, Inc.
HealthcareNASDAQ:OSUR · NASDAQ Global Select
-$0.01 today
Vol 0.49M · Avg 0.61M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-20.2%
avg 1.2%
ROIC
-18.6%
avg 1.2%
ROA
-17.0%
avg 1.2%
Analysis
ROA is currently the strongest return metric at -17.0% versus its period average of 1.2%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Carrie Eglinton Manner | President, Chief Executive Officer & Director | $898,040.00 | — | 51 | $2.19M | 3.18% |
Kenneth J. McGrath | Chief Financial Officer | $577,440.00 | — | 54 | $589,562.00 | 0.86% |
Karen Davies | Diagnostics R&D & Chief Technologist | — | — | — | — | — |
Amy Steigerwalt | Senior Vice President of Human Resources | — | — | — | — | — |
Michele Anthony | Senior Vice President, Chief Accounting Officer, Controller & Assistant Secretary | — | — | 52 | $185,788.00 | 0.27% |
Zachary Wert | Senior Vice President of Global Operations | — | — | — | — | — |
Jason Michael Plagman | Vice President of Investor Relations | — | — | — | $111,823.00 | 0.16% |
Rafal Iwasiow | Sample Management Solutions R&D & Chief Scientist | — | — | — | — | — |
David A. Rappaport | Senior Vice President of Corporate Development, Strategy & Integration | — | — | — | $126,335.00 | 0.18% |
Stefano Taucer | General Counsel & Corporate Secretary | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
8
$550,992.02
Sells
0
$0.00
Net Sentiment
+$550,992.02
Net buying
Most Active
Boyd Steven Kyle
3 transactions
Analysis
Insiders reported 8 buys worth $550,992.02 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $550,992.02. Boyd Steven Kyle was the most active insider with 3 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +10.9% | +0.6% (13yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at +10.9% over three years. Forward estimates point to Revenue at +0.6% (13yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Genfit S.A.
GNFT
$445.68M
Prenetics Global Limited
NASDAQ:PRE
$367.72M
Nautilus Biotechnology, Inc.
NASDAQ:NAUT
$284.66M
Perspective Therapeutics, Inc.
AMEX:CATX
$227.89M
Utah Medical Products, Inc.
NASDAQ:UTMD
$216.00M
Profound Medical Corp.
NASDAQ:PROF
$200.47M
Protara Therapeutics, Inc.
NASDAQ:TARA
$150.50M
Neonc Technologies Holdings, Inc.
NASDAQ:NTHI
$94.98M
Neuronetics, Inc.
NASDAQ:STIM
$92.55M
Nyxoah S.A.
NASDAQ:NYXH
$55.05M
Who manages OSUR?
OraSure Technologies, Inc. (OSUR) lists 10 active executives. The top listed executive is Kenneth J. McGrath, Chief Financial Officer.
Are OSUR insiders buying or selling?
Recent insider activity shows net buying of $4.54M.
Explore More
Continue the stock analysis
Jump to another research area for this company.